Bridgitte Shen Lee

1 week ago | optometrytimes.com | Bridgitte Shen Lee |Emily Kaiser Maharjan |Jordana Joy

May 28, 2025By Bridgitte Shen Lee, OD, FAAO, FBCLA, FEAOO, details the key takeaways from a poster presentation she participated in during ARVO 2025. In detailing a poster presentation given on perfluorohexyloctane (PFHO) (Miebo) on a dry eye disease treatment, Bridgitte Shen Lee, OD, FAAO, FBCLA, FEAOO, highlighted 2 key takeaways from the research. The first takeaway emphasizes the study's robust methodology.

1 week ago | optometrytimes.com | Bridgitte Shen Lee |Emily Kaiser Maharjan |Jordana Joy

Bridgitte Shen Lee, OD, FAAO, FBCLA, FEAOO, presented a poster at ARVO 2025 discussing the early adoption and utilization of perfluorohexoloctane (Miebo), a new medication for dry eye disease. This medication is unique as the first of its kind in the prescription dry eye treatment market, which currently includes 7 FDA-approved medications. The research utilized IQVIA longitudinal prescription claims data from September through November 2023, coinciding with Miebo's FDA approval in September.